Was $25 what, about a week ago? I think that the market is learning the hard way that these guys are going to be second out of the gate by two to three years if they ever get out of the gate. t
I haven't heard from you guys, I hope it's nothing I said. I think the MTP inhibitor from AEGR will make an excellent second line agent after Mipo. Here's an article for you to look over:
Good luck you guys, I'm open for a board position along with you once Mipo gets approved. I want to be like Dr. K, support the competitor but get a pay check from you guys. Thanks in advance, t
Unless you're on the BOD or the CEO you need to go and listen to ISIS last CC and hear for yourself Dr. K noting that the two companies have disconcordant data with ISIS clearly the winner. It's nice that Dr. K could pick up some additional spending money from AEGR though. T
endspeed: I sat on an Isis investor presentation wherein they discussed clinical protocols and recall that patients were placed on a restricted fat diet going into the trial to stabilize base cholesterol levels. I do not see that as remarkable one way or the other – The premise is that a trial clinician would want to stabilize cholesterol levels to calculate as accurately as possible changes in cholesterol attributable to the drug without having to worry about what patient ate the night before (e.g. steak or carrots). I too am a small time investor with an interest in biotech – in terms of Beer, I’ll follow up on your remarks ,you are right one should not act cavalier towards the FDA nor the investment community.